ENFERMEDADES DIGESTIVAS
Instituto de Investigación Sanitaria Aragón
Zaragoza, EspañaPublikationen in Zusammenarbeit mit Forschern von Instituto de Investigación Sanitaria Aragón (4)
2024
-
A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study)
Gastroenterologia y Hepatologia, Vol. 47, Núm. 8, pp. 821-833
-
Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study)
Gastroenterologia y Hepatologia, Vol. 47, Núm. 7, pp. 750-758
-
Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA
Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290
2023
-
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91